Search Clinical Trials in the EU

Duration

Visits

Phase

Intake methods

Post-Trial Drug Access

Drugs

Locations

Clinical Specialty

421-440 of 847 trials

Chronic Graft-Versus-Host Disease: Axatilimab Treatment

We are studying whether axatilimab, combined with corticosteroids, helps improve symptoms in patients with moderate to severe chronic graft-versus-host disease. This trial compares its effects to a placebo.

Chronic Graft-Versus-Host DiseaseConfirmation phase (III)>20 visits Post-Trial Drug Access Investigational Medicines Cost ReimbursementHematologyInfectious Diseases

Pamidronate for Pain in Sternocostoclavicular Hyperostosis

We are studying whether pamidronate can help reduce pain in patients with sternocostoclavicular hyperostosis. This trial will also look at improvements in daily activities and overall health.

Inflammation of the Sternal RegionSternocostoclavicular Hyperostosis1-2 yearsConfirmation phase (III)≤5 visits Post-Trial Drug Access Standard MedicinesOrthopedics and TraumatologyRheumatology

Paroxysmal Nocturnal Hemoglobinuria: Pozelimab and Cemdisiran Therapy

We are studying the long-term safety and effectiveness of a combination therapy for adults with Paroxysmal Nocturnal Hemoglobinuria. This trial will help us understand its impact on symptoms like fatigue and hemoglobin levels.

Paroxysmal Nocturnal Hemoglobinuria>2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteHematologyInternal Medicine

Acne Vulgaris: N-Acetyl-GED-0507-34-Levo Gel

We are testing a new gel for people with acne vulgaris to see if it is safe and effective compared to a placebo. Participants will apply the gel once daily for the study.

Acne3-6 monthsConfirmation phase (III)≤5 visits Post-Trial Drug Access Investigational MedicinesDermatology

Hypereosinophilic Syndrome: Depemokimab Study

We are investigating whether Depemokimab can help adults with Hypereosinophilic Syndrome manage their symptoms better than a placebo. This study aims to provide insights into its effectiveness and safety.

Hypereosinophilic Syndrome1-2 yearsConfirmation phase (III)Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteHematologyInternal Medicine

Myotonic Dystrophy Type 1: DYNE-101 Treatment Study

We are evaluating the safety and effects of a new treatment, DYNE-101, for people with Myotonic Dystrophy Type 1. The study aims to see how it impacts muscle health and overall well-being.

Myotonic Dystrophy>2 yearsSafety phase (I)Efficacy phase (II)16-20 visits Post-Trial Drug Access Investigational Medicines Partially RemoteNeurologyOrthopedics and Traumatology

Multiple Myeloma: Teclistamab with Lenalidomide

We are studying a new treatment combining teclistamab and lenalidomide for patients with newly diagnosed multiple myeloma after stem cell transplant. The aim is to see if this combination works better than lenalidomide alone in maintaining remission.

Newly Diagnosed Multiple MyelomaConfirmation phase (III)Post-Trial Drug Access No Placebo Standard Medicines Cost Reimbursement Partially RemoteHematologyOncology

Cirrhosis Treatment: Pegozafermin Study

We are studying a new medication, pegozafermin, for individuals with compensated cirrhosis due to MASH. The goal is to see if it can improve liver health and reduce related health risks compared to a placebo.

Chronic Liver Disease and Cirrhosis>2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteEndocrinologyHepatology

Advanced Solid Tumors and Blood Cancer: Durvalumab and Tremelimumab Study

We are testing the safety and early effectiveness of Durvalumab alone and with Tremelimumab in children with advanced solid tumors and blood cancers. This study aims to find the best dosage and understand how these treatments work.

Malignant Solid TumorSafety phase (I)Efficacy phase (II)6-10 visits Post-Trial Drug Access No Placebo Standard MedicinesOncologyPediatrics

Brivaracetam for Childhood Absence Epilepsy

We are studying whether brivaracetam is effective and safe for children and young adults aged 2 to 25 with childhood or juvenile absence epilepsy. This trial aims to provide insights into its use as a standalone treatment.

Childhood Absence Epilepsy3-6 monthsEfficacy phase (II)Confirmation phase (III)6-10 visits Post-Trial Drug Access Standard Medicines Cost Reimbursement Partially RemoteNeurologyPediatrics

HER2-Altered Cancers: Zongertinib Study

We are testing whether zongertinib can help people with advanced solid tumors that have HER2 mutations or overexpression. The study will evaluate its effectiveness, safety, and how patients respond to the treatment.

HER2-mutated or overexpressed/amplified solid tumorsEfficacy phase (II)Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteOncology

Uncontrolled Asthma: Dupilumab vs. High Dose ICS

We are studying whether adding dupilumab to medium dose asthma medication helps reduce severe asthma attacks better than increasing the dose of current treatments. This trial is for adolescents and adults with uncontrolled asthma.

Asthma1-2 yearsMonitoring phase (IV)Post-Trial Drug Access Investigational Medicines Partially RemoteAllergologyPulmonology

Crohn's Disease: AZD7798 Treatment Study

We are investigating how well AZD7798 works and its safety for people with moderate to severe Crohn's disease. This study will help us understand its effects on disease activity and overall health.

Crohn's Disease1-2 yearsEfficacy phase (II)11-15 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteGastroenterology

Psilocybin Therapy for Depression in Serious Illnesses

We are studying whether medium/high doses of psilocybin can help reduce depression and anxiety in patients with COPD, ALS, MS, or APD. This research aims to improve their quality of life and support their caregivers.

Chronic Respiratory and Neurological Disorders≤3 monthsEfficacy phase (II)6-10 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemotePsychiatryPulmonology

Acute Myeloid Leukemia: KO-539 Treatment Study

We are testing a new drug called KO-539 in patients with relapsed or refractory acute myeloid leukemia. The goal is to see if it is safe and effective for those with specific genetic mutations.

Relapsed Acute Myeloid Leukemia≤3 monthsSafety phase (I)Efficacy phase (II)6-10 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteHematologyOncology

B-Cell Acute Lymphoblastic Leukemia: Inotuzumab Ozogamicin Study

We are examining whether Inotuzumab can help adults with B-Cell Acute Lymphoblastic Leukemia achieve MRD negativity before stem cell transplantation. The study will also look at treatment safety and survival rates.

Acute Lymphoblastic Leukemia>2 yearsEfficacy phase (II)Post-Trial Drug Access No Placebo Standard MedicinesHematologyOncology

ANCA-Associated Vasculitis: LNP023 (iptacopan) Study

We are testing a new treatment for patients with active ANCA-associated vasculitis to see if it helps achieve lasting remission compared to standard care. The study will also evaluate its impact on disease relapse and kidney health.

Microscopic PolyangiitisGranulomatosis with Polyangiitis1-2 yearsEfficacy phase (II)Post-Trial Drug Access Standard Medicines Cost Reimbursement Partially RemoteInternal MedicineRheumatology

Advanced Solid Tumors: MOST Plus Treatment Study

We are studying a new maintenance treatment for patients with advanced solid tumors to see if it helps keep the disease stable after initial therapy. This trial compares ongoing treatment with stopping the therapy to understand the best approach.

Advanced or Metastatic Cancers>2 yearsEfficacy phase (II)≤5 visits Post-Trial Drug Access No Placebo Standard MedicinesOncology

Systemic Lupus Erythematosus: Obexelimab Study

We are studying a new medication, Obexelimab, for patients with systemic lupus erythematosus to see if it can lower disease activity and reduce fatigue. This trial compares its effects to a placebo treatment.

Systemic Lupus Erythematosus6-12 monthsEfficacy phase (II)6-10 visits Post-Trial Drug Access Investigational Medicines Cost ReimbursementInternal MedicineRheumatology

Kidney Transplant Rejection: INTERCEPT Study

We are studying whether adding TCZ to standard treatment helps kidney transplant recipients with chronic rejection maintain better kidney function. The trial also looks at the safety of this treatment and its effects on overall health.

Chronic Active Antibody-Mediated Rejection>2 yearsConfirmation phase (III)6-10 visits Post-Trial Drug Access No Placebo Standard Medicines Partially RemoteInternal MedicineNephrology

Search Clinical Trials in the European Union